Pre-clinical Data Show Orbus Neich's Combo Bio-engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies
SAN FRANCISCO, Sept. 23 /PRNewswire/ -- OrbusNeich announced today that pre-clinical data involving porcine coronary models demonstrate that the company's Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) may offer advantages to the Cypher(R) sirolimus eluting stent and the XIENCE(TM) V everolimus eluting stent.